Combination treatment for chronic Graft-versus-Host Disease

A Phase II b Study of Axatilimab in Combination With Extracorporeal Photopheresis (ECP) in Chronic Graft-versus-Host Disease

This study is testing a new combination treatment with Axatilimab and light therapy to see if it helps people with chronic Graft-versus-Host Disease who haven't responded well to other treatments.

Quick facts

• Phase: Phase 2
• Study type: Interventional
• Enrollment: 49 (estimated)
• Ages: 12 Years and up
• Sex: All
• Sponsor: University of Miami (Academic / other)
• Drugs / interventions: ruxolitinib, ibrutinib, prednisone, Axatilimab
• Locations: 1 site (Miami, Florida)
• Trial ID: NCT06663722 on ClinicalTrials.gov

What this trial studies

This study evaluates the effectiveness of a combination treatment using Axatilimab and Extracorporeal Photopheresis (ECP) for patients suffering from chronic Graft-versus-Host Disease (cGVHD). Participants must have undergone allogeneic hematopoietic cell transplantation and have experienced inadequate responses to at least two prior lines of therapy. The study aims to determine if this novel combination can improve patient outcomes in managing cGVHD symptoms.

Who should consider this trial

Good fit: Ideal candidates are individuals aged 12 and older who have received allogeneic hematopoietic cell transplantation and have chronic GVHD requiring new therapy.

Not a fit: Patients who have not undergone allogeneic hematopoietic cell transplantation or those with early-stage GVHD may not benefit from this study.

Why it matters

Potential benefit: If successful, this treatment could provide a new effective option for patients with chronic Graft-versus-Host Disease who have not responded to existing therapies.

How similar studies have performed: Other studies have explored treatments for cGVHD, but the specific combination of Axatilimab and ECP is relatively novel and has not been extensively tested together.

Eligibility criteria

Inclusion Criteria:

1. Recipient of allogeneic hematopoietic cell transplantation (HCT).
2. Age greater or equal to 12.
3. Chronic GVHD per 2014 National Institutes of Health Consensus Criteria (NCC) (Jagasia et al. 2015) or overlap syndrome requiring new therapy in patients with at least 2 prior lines of therapy, steroid refractoriness, or steroid dependence:

   1. Prior systemic lines of therapy may include corticosteroids, calcineurin inhibitor (CNI) or sirolimus, or other systemic immunosuppressive agent such as ruxolitinib, belumosudil, or ibrutinib. GVHD prophylaxis does not count as a prior line of therapy.
   2. Steroid refractory is defined as any of the following criteria:

      * i. Manifestations progress despite the use of ≥ 1 mg/kg/day prednisone for at least 1 week
      * ii. Manifestations persist without improvement despite treatment with ≥ 0.5 mg/kg/day or 1 mg/kg every other day for at least four weeks.
      * iii. Recurrence after a CR, or
      * iv. Progression after a PR.
   3. Steroid dependence is defined as inability to control cGVHD symptoms while tapering prednisone below 0.25 mg/kg/day on at least two occasions separated by at least 8 weeks. There must be evidence of clinically active cGVHD.
4. For patients receiving approved or commonly used agents, all GVHD systemic treatments should be discontinued except for corticosteroids and drugs being continued from GVHD prophylaxis at screening.
5. Eastern Cooperative Oncology Group (ECOG) performance status 0-3 as assessed at Screening.
6. Platelet count \> 50,000 platelets/μL and absolute neutrophil count \> 1,000 cells/μL as measured at Screening.
7. Aspartate aminotransferase (AST), alanine aminotransferase (ALT) ≤ 2.5 x upper limit of normal (ULN), unless attributed to presumed cGVHD as measured at Screening.
8. Stable dose of corticosteroids for at least 14 days prior to treatment.
9. Sexually mature individuals must use contraception as described in Section 4.12. For individuals less than 18 years of age, sexual maturity will be determined as per treating pediatrician.

Exclusion Criteria:

1. Pregnancy or breast-feeding.
2. Active relapse of underlying malignancy.
3. History or the presence of interstitial pneumonitis or drug-related pneumonitis.
4. Active gastrointestinal (GI) bleeding.
5. Inability to tolerate volume shifts associated with ECP (e.g., inadequate renal, hepatic, pulmonary and cardiac function (ejection fraction (EF) \< 40%) per Investigator discretion.
6. History of myositis.
7. History of splenectomy.
8. History of pancreatitis.
9. History of other malignancy (within 3 years of Screening) unless treated with curative intent and approved by Principal Investigator (PI).
10. Significant, uncontrolled, or active comorbid conditions or are unable to adhere to the study requirements.
11. Acquired Immune Deficiency Syndrome (AIDS) or active hepatitis B (Hep B) or active hepatitis C (Hep C) infection.
12. Prior colony-stimulating factor-1 (CSF-1R) targeted therapies.
13. Prior history of ECP treatment failure or intolerance.
14. Intolerance to methoxsalen, heparin, or citrate products.
15. Patients with aphakia due to risk of increased retinal damage or photosensitive disease (albinism, systemic lupus erythematosus, porphyria).
16. Lack of stable IV access. Acceptable forms include central venous catheter, peripherally inserted central catheter (PICC), or peripheral IV line per institutional guidelines.
17. Insurance denial of coverage for the ECP procedure.

Where this trial is running

Miami, Florida

• University of Miami — Miami, Florida, United States (Recruiting)

Study contacts

• Principal investigator: Trent P Wang, DO — University of Miami
• Study coordinator: Trent P Wang, DO

Conditions Chronic Graft Versus Host Disease; cGVHD